Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
EBIATShares Issued
Ratios

DiaMedica Therapeutics (DMAC) EBIAT (2018 - 2019)

DiaMedica Therapeutics' EBIAT history spans 2 years, with the latest figure at -$2.5 million for Q4 2019.

  • For Q4 2019, EBIAT fell 26.4% year-over-year to -$2.5 million; the TTM value through Dec 2019 reached -$10.6 million, down 85.72%, while the annual FY2025 figure was -$32.8 million, 34.18% down from the prior year.
  • EBIAT reached -$2.5 million in Q4 2019 per DMAC's latest filing, down from -$2.4 million in the prior quarter.
  • In the past five years, EBIAT ranged from a high of -$650000.0 in Q1 2018 to a low of -$3.3 million in Q1 2019.